Bioequivalence Study of Pimavanserin 34 mg Capsule
Status:
COMPLETED
Trial end date:
2024-03-09
Target enrollment:
Participant gender:
Summary
An open-label, balanced, randomized, two treatment, two sequence, two period, two way cross-over, single dose bioequivalence study of Pimavanserin 34 mg Capsule of Humanis Sağlık A.Ş., Turkey and NUPLAZID® (Pimavanserin) capsules of Acadia Pharmaceuticals Inc. San Diego, CA 92130 USA in normal, healthy, adult, human subjects under fasting condition.